Chemical modification study of antisense gapmers

Nucleic Acid Therapeutics

Volumn 22, Issue 5, 2012, Pages 344-359

  Stanton, Robert ^a   Sciabola, Simone ^a   Salatto, Christopher ^a   Weng, Yan ^a   Moshinsky, Debra ^a   Little, Jeremy ^a   Walters, Evan ^a   Kreeger, John ^a   Dimattia, Debra ^a   Chen, Tracy ^a   Clark, Tracey ^a   Liu, Mei ^a   Qian, Jessie ^a   Roy, Marc ^a   Dullea, Robert ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE GAPMER; ANTISENSE OLIGONUCLEOTIDE; GLUCOCORTICOID; LOCKED NUCLEIC ACID; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADENOSINE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CYTIDINE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GUANOSINE; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; OXAZINES; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; THYMIDINE; TRANSFECTION; TRANSITION TEMPERATURE;

EID: 84870197940     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0366     Document Type: Article

References (55)

1. AKDIM, F., VISSER, M., TRIBBLE, D., BAKER, B., STROES, E., YU, R., FLAIM, J., SU, J., STEIN, E., and KASTELEIN, J. (2010). Effect of mipomersen, an apolipoprotein b synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiology 105, 1413-1419.
2. BARTHEL, A., and SCHMOLL, D. (2003). Novel concepts in insulin regulation of hepatic gluconeogenesis. Am. J. Physiol. 285, E685-E692. (Pubitemid 37176418)
3. BELL, N., and MICKLEFIELD, J. (2009). Chemical modification of oligonucleotides for therapeutic, bioanalytical and other applications. ChemBioChem 10, 2691-2703.
4. BELTINGER, C., SARAGOVI, H., SMITH, R., LESAUTEUR, L., SHAH, N., DEDIONISIO, L., CHRISTENSEN, L., RAIBLE, A., JARETT, L., and GEWIRTZ, A. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
5. BENNETT, C., and SWAYZE, E. (2010). RNA Targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293.
6. BRAMSEN, J., and KJEMS, J. (2011). Chemical modification of small interfering RNA. In: Antiviral RNAi: Methods in Molecular Biology. R. van Rij, ed. (Springer, New York). pp 77-103.
7. BRAMSEN, J., LAURSEN, M., NIELSEN, A., HANSEN, T., BUS, C., LANGKJAR, N., BABU, B.R., HÃxJLAND, T., ABRAMOV, M., VAN AERSCHOT, A. et al. (2009). A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37, 2867-2881.
8. CANTOR, C.R., WARSHAW, M.M., and SHAPIRO, H. (1970). Oligonucleotide interactions. III. Circular dichroism studies of the conformation of deoxyoligonucleolides. Biopolymers 9, 1059-1077.
9. CHU, J.W., MATTHIAS, D.F., BELANOFF, J., SCHATZBERG, A., HOFFMAN, A.R., and FELDMAN, D. (2001). Successful longterm treatment of refractory Cushing's disease with high dose mifepristone (RU-486). J. Clin. Endocrinol.Metab. 86, 3568-3573. (Pubitemid 32755945)
10. CONSOLI, A., NURJHAN, N., CAPANI, F., and GERICH, J. (1989). Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38, 550-557. (Pubitemid 19125601)
11. CUMMINS, L., OWENS, S., RISEN, L., LESNIK, E., FREIER, S., MCGEE, D., GUINOSSO, C., and COOK, P. (1995). Characterization of fully 2¢-modified oligoribonucleotide heteroand homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 23, 2019-2024.
12. FASMAN, G.D.E. (1975). Handbook of Biochemistry and Molecular Biology. (CRC Press, Cleveland, OH). p. 589.
13. FLANAGAN, W.M., WOLF, J.J., OLSON, P., GRANT, D., LIN, K., WAGNER, R.W., and MATTEUCCI, M.D. (1999). A cytosine analog that confers enhanced potency to antisense oligonucleotides. Proc. Natl. Acad. Sci. 96, 3513-3518. (Pubitemid 29168940)
14. FLUITER, K., FRIEDEN, M., VREIJLING, J., ROSENBOHM, C., DE WISSEL, M.B., CHRISTENSEN, S.M., KOCH, T., ØRUM, H., and BAAS F. (2005). On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. ChemBioChem 6, 1104-1109. (Pubitemid 40825353)
15. FRIEDEN, M., and ØRUM, H. (2008). Locked nucleic acid holds promise in the treatment of cancer. Curr. Pharm. Des. 14, 1138-1142. (Pubitemid 351982560)
16. GAGNER, J.P., and DROUIN, J. (1987). Tissue-specific regulation of pituitary proopiomelanocortin gene transcription by corticotrophin-releasing hormone, 3'5'-cyclic adenosine monophosphate and glucocorticoids. Mol. Endocrinol. 1, 677-682. (Pubitemid 17166931)
17. GEARY, R., YU, R., and LEVIN, A. (2001). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2, 562-574.
18. GREENBERGER, L., HORAK, I., FILPULA, D., SAPRA, P., WESTERGAARD, M., FRYDENLUND, H., ALBÆK, C., SCHRØDER, H., and ØRUM, H. (2008). A RNA antagonist of hypoxia-inducible factor-1A, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7, 3598-3608.
19. HEID, C.A., STEVENS, J., LIVAK, K.J., and WILLIAMS, P.M. (1996). Real time quantitative PCR. Genome Res. 6, 986-994. (Pubitemid 26388091)
20. JACOBSON, P.B., VON GELDERN, T.W., OHMAN, L., OSTERLAND, M., WANG, J., ZINKER, B., WILCOX, D., NGUYEN, P.T., MIKA, A., FUNG, S. et al. (2005). Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J. Pharmacol. Exp. Ther. 314, 191-200. (Pubitemid 41058255)
21. JEPSEN, J., SORENSEN, M., and WENGEL, J. (2004). Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 14, 130-146. (Pubitemid 38987382)
22. JEPSEN, J., and WENGEL, J. (2004). LNA-Antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Dev. 4, 188-194. (Pubitemid 44111950)
23. KAWASAKI, A.M., CASPER, M.D., FREIER, S.M., LESNIK, E.A., ZOUNES, M.C., CUMMINS, L.L., GONZALEZ, C., and COOK, P.D. (1993). Uniformly modified 2¢-deoxy-2¢-fluorophosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36, 831-841. (Pubitemid 23118776)
24. KOSHKIN, A., RAJWANSHI, V., and WENGEL, J. (1998a). Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides. Tetrahedron Lett. 39, 4381-4384. (Pubitemid 28240070)
25. KOSHKIN, A., SINGHA, S., NIELSENB, P., RAJWANSHIA, V., KUMARA, R., MELDGAARDA, M., OLSENC, C., and WENGEL, J. (1998b). LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630. (Pubitemid 28108183)
26. LANFORD, R.E., HILDEBRANDT-ERIKSEN, E.S., PETRI, A., PERSSON, R., LINDOW, M., MUNK, M.E., KAUPPINEN, S., and ORUM, H. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201.
27. LIANG, Y., OSBORNE, M.C., MONIA, B.P., BHANOT, S., WATTS, L.M., SHE, P., DECARLO, S.O., CHEN, X., and DEMAREST, K. (2005). Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54, 848-855. (Pubitemid 40827198)
28. LOK, C., VIAZOVKINA, E., MIN, K., NAGY, E., WILDS, C., DAMHA, M., and PARNIAK, M. (2002). Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2¢-deoxy-2¢-fluoro-d- arabinose and 2¢-deoxyribose nucleotides. Biochemistry 41, 3457-3467. (Pubitemid 34214044)
29. MALHOTRA, M., NAMBIAR, S., RENGASWAMY, V., PRAKASH, S. (2011). Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. Expert Opin. Drug Discov. 6, 269-289.
30. MANOHARAN, M. (1999). 2¢-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta 1489, 117-130.
31. MEIJERINK, J., MANDIGERS, C., LOCHT, L.V.D., TÖ NNISSEN, E., GOODSAID, F., and RAEMAEKERS, J. (2001). A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative realtime PCR. J. Mol. Des. 3, 55-61. (Pubitemid 32440243)
32. MONIA, B.P., LESNIK, E.A., Gonzalez, G., LIMA W.F., McGee, D., GUINOSSO, J. C., Kawasaki, A., COOK, P., and FREIER, S. (1993). Evaluation of 2¢-modified oligonucleotides containing 2¢-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522. (Pubitemid 23195583)
33. OBIKA, S., NANBU, D., HARI, Y., ANDOH, J., MORIO, K., DOI, T., and IMANISHI, T. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2¢-O,4¢-C-methyleneribonucleosides. Tetrahedron Lett. 30, 5401-5404. (Pubitemid 28295121)
34. OHRT, T., and SCHWILLE, P. (2008). siRNA Modifications and Sub-Cellular Localization: A Question of Intracellular Transport? Curr. Pharm. Des. 14, 3674-3685.
35. OPHERK, C., TRONCHE, F., KELLENDONK, C., KOHLMULLER, D., SCHULZE, A., SCHMID, W., and SCHUTZ, G. (2004). Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in strptozotocin-induced diabetes mellitus. Mol. Endocrinol. 18, 1346-1353. (Pubitemid 38692174)
36. ORTEGA, J.A., BLAS, J.R., OROZCO, M., GRANDAS, A., PEDROSO, E., and ROBLES, J. (2007). Binding affinities of oligonucleotides and PNAs containing phenoxazine and GClamp cytosine analogues are unusually sequence-dependent. Org. Lett. 9, 4503-4506.
37. PRAKASH, T.P., ALLERSON, C.R., DANDE, P., VICKERS, T.A., SIOUFI, N., JARRES, R., BAKER, B.F., SWAYZE, E.E., GRIFFEY, R.H., and BHAT, B. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247-4253. (Pubitemid 40884928)
38. RAAL, F., SANTOS, R., BLOM, D., MARAIS, A., CHARNG, M., CROMWELL, W., LACHMANN, R., GAUDET, D., TAN, J., CHASAN-TABER, S. et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebocontrolled trial. Lancet 375, 998-1006.
39. SAZANI, P., ASTRIAB-FISCHER, A., and KOLE, R. (2003). Effects of base modifications on antisense properties of 2¢-Omethoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug Dev. 13, 119-128.
40. SETH, P.P., SIWKOWSKI, A., ALLERSON, C.R., VASQUEZ, G., Lee, S., PRAKASH, T.P., WANCEWICZ, E.V., WITCHELL, D., and SWAYZE, E.E. (2009). Short antisense oligonucleotides with novel 2¢-4¢ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13.
41. SHUKLA, S., SUMARIA, C., and PRADEEPKUMAR, P. (2010). Exploring chemical modifications for siRNA Therapeutics: a structural and functional outlook. ChemMedChem 5, 328-349.
42. SOHAIL, M., and SOUTHERN, E. (2000). Selecting optimal antisense reagents. Adv. Drug Deliv. Rev. 44, 23-34.
43. STEIN, C.A. (1999). Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim. Biophys. Acta 1489, 45-52.
44. STEIN, C.A., Subasinghe, C., Shinozuka, K., and Cohen, J.S. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209-3221.
45. STRAARUP, E.M., FISKER, N., HEDTJÄ RN, M., LINDHOLM, M.W., ROSENBOHM, C., AARUP, V., HANSEN, H.F., ØRUM, H., RODE-HANSEN, J.B., and KOCH, T. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38, 7100-7111.
46. SWAYZE, E.E., SIWKOWSKI, A.M., WANCEWICZ, E.V., MIGAWA, M.T., WYRZYKIEWICZ, T.K., HUNG, G., MONIA, B.P., BENNETT, C.F. (2006). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700. (Pubitemid 46232083)
47. TATA, J.R. (2002). Signaling through nuclear receptors. Nat. Rev. Mol. Cell Biol. 3, 702-710.
48. UESUGI, S., MIKI, H., IKEHARA, M., IWAHASHI, H., and KYOGOKU, Y.A. (1979). Linear relationship between electronegativity of 2'-substituent and conformation of adenine nucleosides. Tetrahedron Lett. 42, 4073-4076.
49. VAN DEN BERGHE, G. (1996). Disorders of gluconeogenesis. J. Inherit. Metab. Dis. 19, 470-477. (Pubitemid 26302523)
50. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSO, T., HÖ KFELT, T., BROBERGER, C., PORRECA, F., LAI, J., REN, K. et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. PNAS 97, 5633-5638. (Pubitemid 30313770)
51. WATTS, J., COREY, D. (2010). Clinical status of duplex RNA. Bioorg. Med. Chem. Lett. 20, 3203-3207.
52. WATTS, L.M., MANCHEM, V.P., LEEDOM, T.A., RIVARD, A.L., MCKAY, R.A., BAO, D., NEROLADAKIS, T., MONIA, B.P., BODENMILLER, D.M., CAO, J.X. et al. (2005). Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54, 1846-1853. (Pubitemid 40770776)
53. WILDS, C.J., MAIER, M. A., TERESHKO, V., MANOHARAN, M., and EGLI, M. (2002). Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-Clamp. Angew. Chem. Int. 41, 115-117. (Pubitemid 34076118)
54. YUAN, X., NAGUIB, S., and WU, Z. (2011). Recent advances of siRNA delivery by nanoparticles. Expert Opin. Drug Deliv. 8, 521-536.
55. ZHAO, Q., TEMSAMANI, J., IADAROLA, P.L., JIANG, Z., and AGRAWAL, S. (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51, 173-182. (Pubitemid 26018763)